S*BIO’s Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models Date: February 28, 2011 Client: S*BIO Pte Ltd Summary: SINGAPORE, Feb. 28, 2011 - S*BIO Pte Ltd today announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models. In vivo and in vitro data on SB2343 were presented at American Association of Cancer Research (AACR) Special Conference on Targeting PI3K/mTOR Signaling in Cancer held in San Francisco.
		MorphoSys Announces Change in Executive Management Board Date: February 24, 2011 Client: MorphoSys AG Summary: MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that Jens Holstein, currently Regional CFO for the region EME (Europe/Middle East) of Fresenius Kabi AG and Managing Director of Fresenius Kabi Deutschland GmbH, will succeed Dave Lemus both as Chief Financial Officer of MorphoSys AG and as a member of the executive management board (Vorstand). Mr. Lemus will step down from his position as CFO with the Company in March 2011 to pursue other opportunities. Mr. Holstein will take up his position on May 1, 2011.
		AVI BioPharma to Present Company Overview at the 2011 Citi Global Healthcare Conference Date: February 23, 2011 Client: AVI BioPharma Summary: AVI BioPharma (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the 2011 Citi Global Healthcare Conference in New York City on Tuesday, March 1, at 9:30 a.m. Eastern Time. Chris Garabedian, AVI's president and CEO, will provide a company overview.
		StemCells, Inc. to Present at New York Stem Cell Summit Date: February 23, 2011 Client: StemCells, Inc. Summary: StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn, President and CEO, and Stephen Huhn, M.D., Vice President and Head of CNS Program, have each been invited to speak at the 6th Annual New York Stem Cell Summit to be held March 1 at Bridgewaters in New York City. This year's Summit will feature a panel discussion on stem cell approaches to spinal cord injury, including the Company's recently authorized Phase I/II clinical trial of its HuCNS-SC(R) cells (purified human neural stem cells) in chronic spinal cord injury, which will be conducted in Switzerland.
		INTERVIEW-AVI BioPharma ups focus on muscular dystrophy Date: February 15, 2011 Client: AVI BioPharma Summary: AVI BioPharma Inc plans to conduct this year a second mid-stage trial of its experimental drug for a type of muscular dystrophy and could launch a pivotal trial as early as the second half of next year, according to the biotech company's new chief executive officer.
		Arkansas Blue Cross and Blue Shield Selects MedAssurant For Care Coordination and Enhancement Date: February 15, 2011 Client: MedAssurant, Inc. Summary: BOWIE, Md. – Feb. 15, 2011 – MedAssurant, Inc., a leading provider of data-driven healthcare solutions, today announced that Arkansas Blue Cross and Blue Shield, Arkansas’ largest health insurer, has selected MedAssurant’s SmartCare solution suite to improve care coordination and enhancement. SmartCare, a solution powered by MedAssurant’s advanced data analytics, will enable Arkansas Blue Cross to increase utilization efficiency and improve clinical outcomes for their Medicare Advantage members.
		StemCells, Inc. to Present at BIO CEO & Investor Conference Date: February 8, 2011 Client: StemCells, Inc. Summary: StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference to be held February 14-15 in New York City. Mr. McGlynn is scheduled to speak at 1:00 p.m. Eastern Time on Tuesday, February 15.
		6th Annual New York Stem Cell Summit Presenters Announced Date: February 7, 2011 Summary: PHILADELPHIA, Feb. 7, 2011 – RRY Publications LLC today announced the presenter line-up for the 6th Annual Stem Cell Summit, an event which is slated to bring together the largest gathering of stem cell company executives, scientists, investors and physicians in New York. Participants will learn about investment opportunity in the stem cell marketplace, groundbreaking stem cell products and the growing market potential for the industry.